大B细胞淋巴瘤中CAR-T细胞产品的免疫重建动力学及其对预后的影响
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.
作者信息
Luan Danny, DeWolf Susan, Fei Teng, Raj Sandeep, Shah Gunjan L, Lareau Caleb A, Alhomoud Mohammad, Salles Gilles, Rivas-Delgado Alfredo, Rejeski Kai, Park Jae H, Luttwak Efrat, Luna de Abia Alejandro, Corona Magdalena, Ntrivalas Evangelos, Cassanello Giulio, Gomez-Llobell Marina, Parascondola Allison, Scordo Michael, Hsu Katharine C, Palomba M Lia, Perales Miguel-Angel, Shouval Roni
机构信息
Department of Medicine, Weill Cornell Medicine, New York, New York.
Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Blood Cancer Discov. 2025 Mar 4;6(2):119-130. doi: 10.1158/2643-3230.BCD-24-0163.
Abstract
This study reveals differences in IR patterns after CAR-T therapy in patients with large B-cell lymphoma, with early NK cell recovery emerging as a key predictor of survival. These findings provide potential future avenues of research for improving patient outcomes and tailoring post-therapy management strategies to mitigate relapse risk.
摘要
本研究揭示了大B细胞淋巴瘤患者接受CAR-T治疗后免疫重建模式的差异，早期自然杀伤细胞恢复是生存的关键预测指标。这些发现为未来改善患者预后以及制定治疗后管理策略以降低复发风险提供了潜在的研究途径。
相似文献
1
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.大B细胞淋巴瘤中CAR-T细胞产品的免疫重建动力学及其对预后的影响
Blood Cancer Discov. 2025 Mar 4;6(2):119-130. doi: 10.1158/2643-3230.BCD-24-0163.
2
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.侵袭性大B细胞淋巴瘤患者在嵌合抗原受体T细胞治疗前进行桥接放疗的疗效。
Front Immunol. 2025 Jan 31;16:1517348. doi: 10.3389/fimmu.2025.1517348. eCollection 2025.
3
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
4
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.弥漫性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞（CAR T）治疗及时给药障碍的真实世界分析。
Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11.
5
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.商业用阿基仑赛注射液与瑞基奥仑赛注射液在大B细胞淋巴瘤中的真实世界比较。
Blood Adv. 2025 Feb 11;9(3):455-462. doi: 10.1182/bloodadvances.2024012992.
6
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing.通过单细胞RNA测序比较阿基仑赛和替雷利珠单抗患者CAR-T细胞产品
J Immunother Cancer. 2025 Jul 28;13(7):e011807. doi: 10.1136/jitc-2025-011807.
7
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.抗 CD19 CAR-T 细胞疗法在老年患者中的应用：GETH-TC/GELTAMO 的多中心真实世界经验。
Transplant Cell Ther. 2024 Oct;30(10):988.e1-988.e11. doi: 10.1016/j.jtct.2024.06.022. Epub 2024 Jul 26.
8
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.苯达莫司汀与氟达拉滨/环磷酰胺在淋巴瘤嵌合抗原受体T细胞治疗前进行淋巴细胞清除的疗效比较
Transplant Cell Ther. 2025 Aug;31(8):549.e1-549.e11. doi: 10.1016/j.jtct.2025.03.012. Epub 2025 Mar 22.
9
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.阿基仑赛与替雷利珠单抗治疗复发或难治性大B细胞淋巴瘤的系统评价与Meta分析
Transplant Cell Ther. 2024 Jun;30(6):584.e1-584.e13. doi: 10.1016/j.jtct.2024.01.074. Epub 2024 Jan 26.
10
Enrichment of CD7CXCR3 CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma.输注产品中CD7CXCR3嵌合抗原受体T细胞的富集与复发或难治性弥漫性大B细胞淋巴瘤的持久缓解相关。
Ann Oncol. 2025 Jul;36(7):749-761. doi: 10.1016/j.annonc.2025.03.011. Epub 2025 Mar 23.
引用本文的文献
1
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应。
Blood Cancer J. 2025 Jul 2;15(1):114. doi: 10.1038/s41408-025-01321-w.
2
Concomitant group A Streptococcus and disseminated mpox infection mimicking relapsed diffuse large B-cell lymphoma.A组链球菌与播散性猴痘感染并存，酷似复发性弥漫性大B细胞淋巴瘤。
JAAD Case Rep. 2025 Apr 26;61:45-50. doi: 10.1016/j.jdcr.2025.04.015. eCollection 2025 Jul.
本文引用的文献
1
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.嵌合抗原受体 T 细胞（CAR T）治疗后与免疫效应细胞相关的血液毒性：从机制到管理。
Lancet Haematol. 2024 Jun;11(6):e459-e470. doi: 10.1016/S2352-3026(24)00077-2. Epub 2024 May 8.
2
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.CD19 CAR T 细胞疗法治疗自身免疫性疾病 - 附随访的病例系列。
N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.
3
Breakthrough of solid tumor treatment: CAR-NK immunotherapy.实体瘤治疗的突破：CAR-NK免疫疗法。
Cell Death Discov. 2024 Jan 20;10(1):40. doi: 10.1038/s41420-024-01815-9.
4
CAR-T cell manufacturing: Major process parameters and next-generation strategies.CAR-T 细胞生产：主要工艺参数和下一代策略。
J Exp Med. 2024 Feb 5;221(2). doi: 10.1084/jem.20230903. Epub 2024 Jan 16.
5
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.淋巴细胞耗竭——嵌合抗原受体 T 细胞治疗周期中的一个重要但被低估的部分。
Front Immunol. 2023 Dec 22;14:1303935. doi: 10.3389/fimmu.2023.1303935. eCollection 2023.
6
Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.血液系统恶性肿瘤嵌合抗原受体（CAR）-T 细胞治疗后的感染。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14157. doi: 10.1111/tid.14157. Epub 2023 Oct 3.
7
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.针对间皮素的 T 细胞受体融合构建细胞疗法治疗难治性实体瘤：1/2 期试验中期结果。
Nat Med. 2023 Aug;29(8):2099-2109. doi: 10.1038/s41591-023-02452-y. Epub 2023 Jul 27.
8
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.CD19 CAR T 细胞疗法和预防性阿那白滞素治疗复发或难治性淋巴瘤：2 期试验中期结果。
Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul 3.
9
Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel.高剂量或长期使用皮质类固醇对接受Tisagenlecleucel 治疗的复发或难治性 B 细胞淋巴瘤患者的预后产生负面影响。
Transplant Cell Ther. 2023 Sep;29(9):573.e1-573.e8. doi: 10.1016/j.jtct.2023.06.018. Epub 2023 Jul 1.
10
Long-term outcomes following CAR T cell therapy: what we know so far.嵌合抗原受体 T 细胞疗法治疗后的长期结果：目前我们所了解的情况。
Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.
Zotero 插件